Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report

BACKGROUND: Increasingly widespread use of programmed cell death protein 1 (PD-1) immune checkpoint inhibitors (ICIs) for treatment of a variety of progressive malignancies continues to reveal a range of immune-related adverse events (irAEs), necessitating immunosuppressive therapy for management. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Hines, Jacobi, Daily, Ellen, Pham, Anh Khoa, Shea, Christopher R., Nadeem, Urooba, Husain, Aliya N., Stadler, Walter M., Reid, Pankti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977267/
https://www.ncbi.nlm.nih.gov/pubmed/33736690
http://dx.doi.org/10.1186/s13256-021-02670-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977267/
https://www.ncbi.nlm.nih.gov/pubmed/33736690
http://dx.doi.org/10.1186/s13256-021-02670-3

Ejemplares similares